Opinion

Video

BCG for treatment of NMIBC

Experts discuss the use of bacille Calmette-Guérin (BCG) as the standard treatment for high-risk non–muscle-invasive bladder cancer (NMIBC), when a patient is considered unresponsive to BCG, and how BCG shortages have impacted clinical practice and urologists in the community.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert in this video
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
1 expert in this video
1 expert is featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.